The purpose of this workshop is to bring together the academic, regulatory and pharmaceutical communities to discuss therapeutic endpoints, trial designs and appropriate patient populations and safety concerns with regards to novel therapeutic approaches for treatment of NAFLD. This meeting will be unique in that it will bring all the important and relevant parties to the table to discuss these critical issues that need resolution before substantial progress can be made in delivering the next generation of therapeutic agents to affected individuals with NAFLD. AASLD and EASL possess the expertise in NAFLD to bridge the current knowledge gaps that regulatory and pharmaceutical industry have identified as important issues hampering development of novel therapeutic agents for NAFLD.
For more information, visit website.
Joint Meeting between
EASL- European Association for the Study of the Liver
AASLD-American Association for the Study of Liver Diseases